Heligenics was formed as an LLC in late 2017 and converted to a C corporation in late 2019. We started with just two employees and a team of advisors. We now have 6 research and administration employees, 6 sales consultants, and our team of advisors has grown as well. We successfully closed our first round of funding and are now taking on clients after building out our wet lab facilities from scratch within the city of Las Vegas.

​

                 Mission                       

 

 

To prevent disease and heal patients afflicted with illness through genomics.

​

​

Our Approach

Based on the GigaAssay technology developed at the University of Nevada Las Vegas in the Schiller Laboratory of Applied Bioinformatics, our GigaAssay is a massively parallel biological assay that can simultaneously measure how millions of genetic variants or other sequence variables affect a molecular function of cell process. To date, there are no other established high-throughput assays that assess biological function.

​

The GigaAssay produces functional genomics data that can be licensed and used for prevention-based approaches and diagnostics. Additionally, for developing new drug therapies or redesigning clinical trials for drugs that have failed a trial due to poor efficacy or safety. Heligenics products will transform the medical industry.